Cardiology Headline News

ATLANTA — A single subcutaneous dose of zilebesiran, an investigational RNA interference agent, significantly reduced 24-hour mean ambulatory and office systolic BP at 6 months vs. placebo when added to other antihypertensive therapy.

ATLANTA — In the TACT2 trial, chelation therapy reduced levels of lead in the blood but did not improve cardiovascular outcomes for adults with diabetes and a prior heart attack.

ATLANTA — In patients with severe aortic stenosis and a small aortic annulus undergoing transcatheter aortic valve replacement, hemodynamic parameters were best with a self-expanding valve, according to data from the SMART trial.

ATLANTA — Adults with obesity, HF with preserved ejection fraction and type 2 diabetes saw marked improvements in HF symptoms and physical function with semaglutide 2.4 mg compared with placebo, despite less than typical weight loss.

ATLANTA — In patients who underwent early angiography for acute MI and had ejection fraction of 50% or more, long-term beta-blocker use did not reduce risk for death or new MI compared with no use, researchers reported.

ATLANTA — In a study of behavioral economics, researchers reported benefits of gamification and money incentives to boost daily step count for patients at high risk for CVD.

ATLANTA — Monthly administration of subcutaneous olezarsen substantially reduced triglyceride levels compared with placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk, according to new phase 2 data.

ATLANTA — A mandibular advancement device may be better for blood pressure lowering compared with continuous positive airway pressure devices for people with obstructive sleep apnea and hypertension, researchers reported.

ATLANTA — In the EMPACT-MI trial, empagliflozin treatment soon after an acute MI did not significantly lower risk for HF hospitalization or death from any cause compared with placebo among patients with increased risk for HF.

ATLANTA — Four weekly infusions of a novel formulation of human apolipoprotein A-I did not reduce a combination of CV endpoints at 90 days for adults with acute MI, multivessel disease and additional CV risk factors, researchers reported.